BIOCHIPS MARKET ANALYSIS

Key Developments

• In May 2024, Visionary Holdings Inc., a leading private education provider specializing in artificial intelligence and life sciences, announced its collaboration with Canada’s B. Braun Biochip Technology Group to form Visionary Biotechnology Group Co., Ltd. in Toronto. This collaboration is expected to significantly influence both economic and social value, enhancing Visionary Group's global impact in biotechnology. It presents notable value for investors in the short, medium, and long term.
• In October 2022, MicrobioSeq (CD Genomics) introduced Phage Whole-Genome Sequencing to aid in the discovery of biomarkers and the development of non-antibiotic treatment methods. Utilizing next-generation sequencing and long-read sequencing technologies, including Illumina HiSeq, Nanopore, and PacBio SMRT sequencing, CD Genomics offers virus/phage sequencing services and supports in-depth research in structural and comparative genomics.
• In October 2022, Thermo Fisher Scientific Inc. enhanced its Applied Biosystems Chromosome Analysis Suite (ChAS) software through a partnership with Genoox, a company specializing in community-driven genomic data. This upgrade enables ChAS users to access Genoox’s cloud-based AI platform. With the integration of Franklin, the software now offers an automated and flexible workflow for immediate, consistent, and reproducible cytogenetic analysis results.